Protocol Ledger

NCT04411472 · Phase III · TERMINATED

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

Interventional Phase III clinical trial protocol NCT04411472 sponsored by AM-Pharma in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-02 Enrollment: 676 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04411472
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)676 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04411472
Protocol FieldVerified Registry Value
NCT IdentifierNCT04411472
Consolidated Lead SponsorAM-Pharma
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment676 participants (ACTUAL)
Registered Start Date2020-11-02
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI